Walvax BioTech - Asset Resilience Ratio

Latest as of June 2025: 2.20%

Walvax BioTech (300142) has an Asset Resilience Ratio of 2.20% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300142 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥308.17 Million

≈ $45.09 Million USD Cash + Short-term Investments

Total Assets

CN¥14.00 Billion

≈ $2.05 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2022)

This chart shows how Walvax BioTech's Asset Resilience Ratio has changed over time. See net assets of Walvax BioTech for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Walvax BioTech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Walvax BioTech.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥308.17 Million	2.2%
Total Liquid Assets	CN¥308.17 Million	2.20%

Asset Resilience Insights

Limited Liquidity: Walvax BioTech maintains only 2.20% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Walvax BioTech Industry Peers by Asset Resilience Ratio

Compare Walvax BioTech's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	1.96%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Guobang Pharma Ltd SHG:605507	Drug Manufacturers - Specialty & Generic	8.47%

Annual Asset Resilience Ratio for Walvax BioTech (2013–2022)

The table below shows the annual Asset Resilience Ratio data for Walvax BioTech.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-0.25%	CN¥-38.16 Million ≈ $-5.58 Million	CN¥15.34 Billion ≈ $2.24 Billion	+0.08pp
2021-12-31	-0.33%	CN¥-45.05 Million ≈ $-6.59 Million	CN¥13.67 Billion ≈ $2.00 Billion	+0.17pp
2020-12-31	-0.50%	CN¥-48.19 Million ≈ $-7.05 Million	CN¥9.65 Billion ≈ $1.41 Billion	+0.18pp
2019-12-31	-0.68%	CN¥-47.52 Million ≈ $-6.95 Million	CN¥7.02 Billion ≈ $1.03 Billion	-0.12pp
2018-12-31	-0.56%	CN¥-40.24 Million ≈ $-5.89 Million	CN¥7.24 Billion ≈ $1.06 Billion	+0.29pp
2017-12-31	-0.84%	CN¥-49.59 Million ≈ $-7.26 Million	CN¥5.88 Billion ≈ $859.84 Million	+0.13pp
2016-12-31	-0.98%	CN¥-61.90 Million ≈ $-9.06 Million	CN¥6.32 Billion ≈ $925.40 Million	-1.43pp
2015-12-31	0.45%	CN¥28.10 Million ≈ $4.11 Million	CN¥6.26 Billion ≈ $915.72 Million	+0.54pp
2013-12-31	-0.09%	CN¥-5.60 Million ≈ $-819.25K	CN¥6.14 Billion ≈ $897.87 Million	--

pp = percentage points

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.04 Billion

CN¥20.79 Billion CNY

Market Cap Rank

#4887 Global

#921 in China

Share Price

CN¥13.00

Change (1 day)

+0.85%

52-Week Range

CN¥10.07 - CN¥14.48

All Time High

CN¥93.63